ClinicalTrials.gg
CompletedNCT02633501Updated Oct 25, 2021Results posted

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

A Phase 2 interventional study of P03277 and Gadobenate dimeglumine in CNS Lesion and Blood Brain Barrier Defect, sponsored by Guerbet. Completed at 28 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by Guerbet · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine a safe and effective dose of a new gadolinium-based contrast agent (GBCA) P03277 based on the Contrast to Noise Ratio (CNR) when comparing with gadobenate dimeglumine (MultiHance®) at 0.1 mmol/kg body weight (BW).

Contrast to Noise Ratio (CNR), a well-known quantitative parameter directly related to contrast medium/GBCA efficacy, was chosen as the primary endpoint in order to have a precise determination of P03277 clinical dose.

This was a multi-center, international, prospective, double-blind, randomized, controlled, parallel dose groups, cross-over with comparator study in male and female subjects presenting with known or highly suspected focal areas of disruption of the Blood Brain Barrier including at least one expected enhancing lesion of minimum 5 mm, who were scheduled to undergo a routine contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System.

Read the detailed description

Two subsets of subjects were included in the study:

  • The subset 1 included the first randomized subject of each study center. Subjects were randomly assigned in a 1:1 ratio to receive 0.05 or 0.1 mmol/kg BW of P03277 and 0.1 mmol/kg BW of gadobenate dimeglumine.
  • Subset 2 was composed of all subjects (except the first one of each study center) selected by the study center. Subjects were randomly assigned in a 1:1:1:1 ratio to receive 0.025, 0.05, 0.1 or 0.2 mmol/kg BW of P03277 and 0.1 mmol/kg BW of gadobenate dimeglumine.

During the course of the study, two MRIs were obtained from each subject: one unenhanced and P03277-enhanced MRI; and one unenhanced and gadobenate dimeglumine-enhanced MRI. MRI images were evaluated off-site by 3 independent blinded readers for the primary endpoint (CNR).

02

Conditions studied

  • CNS Lesion
  • Blood Brain Barrier Defect
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male adult subjects, with known or highly suspected focal areas of disrupted Blood Brain Barrier including at least one expected enhancing lesion of minimum 5 mm (long axis). This lesion had been detected on a previous imaging procedure (computerized Tomography [CT] or MRI).
  • Subject scheduled for a routine contrast-enhanced MRI examination of Central Nervous System for clinical reasons and agreeing to have a second contrast-enhanced MRI examination for the purpose of the study.

Exclusion criteria

Exclusion Criteria:

  • Subject presenting with acute or chronic Grade III (at least) renal insufficiency, defined as an estimated (eGFR) \<60 mL/min/1.73 m² based on one eGFR assessment performed the day of the MRI prior to the first contrast agent injection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    Subset 1 Arm 1

    One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI

    Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI

  • Experimental
    Subset 1 Arm 2

    Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI

    Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI

  • Experimental
    Subset 2 Arm 1

    One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI

    Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI

  • Experimental
    Subset 2 Arm 2

    Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI

    Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI

Interventions

  • DrugP03277

    Single intravenous (IV) bolus injection at a rate of 2 mL/second

    Also known as: Gadopiclenol

  • Single IV bolus injection at a rate of 2 mL/second

    Also known as: MultiHance

  • DeviceMRI
06

What researchers measure

Primary outcomes

  1. Contrast to Noise Ratio (CNR) Difference

    The Contrast-to-Noise Ratio (CNR) was calculated from the signal intensity measurement of maximum 3 enhanced lesions by 3 independent blinded readers. Only lesions detected by both MRIs after lesion tracking were used. The difference in CNR was calculated as follow: CNR (P03277) - CNR (gadobenate dimeglumine).

    Time frame: 1 day procedure

07

Results

Posted May 8, 2019

Participant flow

Participant flow — Overall Study
MilestoneSubset 1 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 1 - P03277 0.1 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.025 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.1 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.2 mmol/kg/Gadobenate Dimeglumine
Started141462636463
Completed121155595348
Not completed23741115
Withdrew: Adverse event001011
Withdrew: Withdrawal by subject212213
Withdrew: Various other reasons0241711
Withdrew: Lost to follow-up000120

Outcome measures

PrimaryContrast to Noise Ratio (CNR) Difference

The Contrast-to-Noise Ratio (CNR) was calculated from the signal intensity measurement of maximum 3 enhanced lesions by 3 independent blinded readers. Only lesions detected by both MRIs after lesion tracking were used. The difference in CNR was calculated as follow: CNR (P03277) - CNR (gadobenate dimeglumine).

Time frame:
1 day procedure
Reported as:
Least squares mean · Ratio
Contrast to Noise Ratio (CNR) Difference
RatioP03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 1P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 1P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 1P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 1P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 2P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 2P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 2P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 2P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 3P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 3P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 3P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 3
Contrast to Noise Ratio (CNR) Difference-10.59 (-14.59 to -6.58)2.18 (-2.67 to 7.03)8.66 (3.52 to 13.79)14.45 (7.64 to 21.25)-14.14 (-23.33 to -4.95)1.91 (-7.28 to 11.10)19.38 (11.42 to 27.34)38.37 (18.62 to 58.12)-23.96 (-33.78 to -14.13)2.47 (-8.39 to 13.32)29.23 (16.05 to 42.41)51.96 (30.36 to 73.55)
Statistical analysis
  • P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 1 · Mixed Models Analysis · Least squares mean: -10.59
  • P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 1 · Mixed Models Analysis · p = 0.1858 (Superiority not confirmed) · Least squares mean: 2.18
  • P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 1 · Mixed Models Analysis · p = 0.0007 (Superiority confirmed) · Least squares mean: 8.66
  • P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 1 · Mixed Models Analysis · p = <0.0001 (Superiority confirmed) · Least squares mean: 14.45
  • P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 2 · Mixed Models Analysis · Least squares mean: -14.14
  • P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 2 · Mixed Models Analysis · p = 0.3384 (Superiority not confirmed) · Least squares mean: 1.91
  • P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 2 · Mixed Models Analysis · p = <0.0001 (Superiority confirmed) · Least squares mean: 19.38
  • P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 2 · Mixed Models Analysis · p = 0.0002 (Superiority confirmed) · Least squares mean: 38.37
  • P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 3 · Mixed Models Analysis · Least squares mean: -23.96
  • P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 3 · Mixed Models Analysis · p = 0.3249 (Superiority not confirmed) · Least squares mean: 2.47
  • P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 3 · Mixed Models Analysis · p = <0.0001 (Superiority confirmed) · Least squares mean: 29.23
  • P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 3 · Mixed Models Analysis · p = <0.0001 (Superiority confirmed) · Least squares mean: 51.96

Adverse events

Collected over Adverse events were recorded from informed consent signature up to one day after the second MRI, up to 22 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
P03277 0.025 mmol/kg0/56 (0%)0/56 (0%)14/56 (25%)
P03277 0.05 mmol/kg0/74 (0%)0/74 (0%)12/74 (16.2%)
P03277 0.1 mmol/kg0/70 (0%)1/70 (1.4%)19/70 (27.1%)
P03277 0.2 mmol/kg0/56 (0%)1/56 (1.8%)18/56 (32.1%)
Gadobenate Dimeglumine0/256 (0%)2/256 (0.8%)57/256 (22.3%)
Most frequent serious events
Most frequent serious events
EventP03277 0.025 mmol/kgP03277 0.05 mmol/kgP03277 0.1 mmol/kgP03277 0.2 mmol/kgGadobenate Dimeglumine
Femoral neck fractureInjury, poisoning and procedural complications0/560/740/701/560/256
Blood creatinine increasedInvestigations0/560/741/700/560/256
SeizureNervous system disorders0/560/740/700/561/256
Meningioma surgerySurgical and medical procedures0/560/740/700/561/256
Most frequent other events
Showing 10 of 85
Most frequent other events
EventP03277 0.025 mmol/kgP03277 0.05 mmol/kgP03277 0.1 mmol/kgP03277 0.2 mmol/kgGadobenate Dimeglumine
Injection site painGeneral disorders0/562/745/707/569/256
HeadacheNervous system disorders4/563/741/700/567/256
Urinary tract infectionInfections and infestations1/561/743/701/564/256
FatigueGeneral disorders2/560/740/702/561/256
Injection site haematomaGeneral disorders0/560/740/702/560/256
Blood pressure increasedInvestigations2/560/741/700/562/256
DizinessNervous system disorders0/560/740/702/564/256
NauseaGastrointestinal disorders0/560/740/701/569/256
Electrocardiogram QT prolongedInvestigations0/560/742/700/560/256
LeukocyturiaRenal and urinary disorders1/562/741/701/565/256

Baseline characteristics

Subjects of subset 1 were only included in the safety assessment. The Full Analysis Set included 240 subjects from subset 2 who had available results for CNR from both unenhanced and enhanced measurements derivable from one MRI by at least one off-site reader. Analyses using the FAS were based on the contrast agent allocated by the randomization.

Age, Continuous
Age, Continuous(years)Subset 2 - P03277 0.025 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.1 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.2 mmol/kg/Gadobenate DimeglumineSubset 1 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 1 - P03277 0.1 mmol/kg/Gadobenate DimeglumineTotal
Mean54.8 ± 10.954.0 ± 14.854.2 ± 14.452.1 ± 13.754.9 ± 13.356.1 ± 1653.8 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Subset 2 - P03277 0.025 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.1 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.2 mmol/kg/Gadobenate DimeglumineSubset 1 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 1 - P03277 0.1 mmol/kg/Gadobenate DimeglumineTotal
Female34393039105157
Male2323312149111
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Subset 2 - P03277 0.025 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.1 mmol/kg/Gadobenate DimeglumineSubset 2 - P03277 0.2 mmol/kg/Gadobenate DimeglumineSubset 1 - P03277 0.05 mmol/kg/Gadobenate DimeglumineSubset 1 - P03277 0.1 mmol/kg/Gadobenate DimeglumineTotal
American Indian or Alaska Native1000001
Asian85842128
Native Hawaiian or Other Pacific Islander0000000
Black or African American11422212
White475549541011226
More than one race0100001
Unknown or Not Reported0000000
08

Study locations

28 sites
  • Northwestern memorial hospital
    Chicago, Illinois 60611, United States
  • Beth israel deaconess medical center
    Boston, Massachusetts 02215, United States
  • QUEST Research Institute
    Farmington Hills, Michigan 48334, United States
  • Penn State milton S. Hershey Medical center
    Hershey, Pennsylvania 17033, United States
  • University of Pensylvania medical center
    Philadelphia, Pennsylvania 19104, United States
  • Temple university hospital
    Philadelphia, Pennsylvania 19140, United States
  • Rhode Island hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of texas McGovern medical school
    Houston, Texas 77030, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • ZNA campus Middelheim
    Antwerp, Belgium
  • Universitair Ziekenhuis Brussel
    Brussel, Belgium
  • Fakultni nemocnice Olomouc
    Olomouc, Czechia
  • Neurology Clinic-Semmelweis Medical University
    Budapest, Hungary
  • Pecsi Tudomany Egyetem Klinikai kozpont Idegsebeszeti Klinica
    Pécs, Hungary
  • Ospedali Riuniti di Ancona
    Ancona, Italy
  • Ospedale san Raffaele
    Milano, Italy
  • AO S. Andrea Universita La Sapienza
    Roma, Italy
  • Azienda policlinico Umberto
    Roma, Italy
  • Asan medical center
    Seoul, Korea, Republic of
  • Samsung medical center
    Seoul, Korea, Republic of
  • Seoul National university hospital
    Seoul, Korea, Republic of
  • Centro medico ABC santa fe
    Mexico City, Mexico
  • Axis heilsa
    Monterrey, Mexico
  • Clinical research institute SC
    Tlanepantla De Baz, Mexico
  • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Oddzial w Gliwicach
    Gliwice, Poland
  • krakowski Szpital specjalistyczny il Jana Pawla II
    Kraków, Poland
  • Samodzielny publiczny szpital
    Lublin, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Jan 2018, 19 months.

Results were first posted in May 2019, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2015
First posted
Dec 17, 2015
StartActual
Jun 2016
Primary completionActual
Jan 2018
CompletionActual
Jan 2018
Results first posted
May 8, 2019
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02633501
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Dec 17, 2015
Start date
Jun 2016
Primary completion
Jan 2018
Completion
Jan 2018
Results posted
May 8, 2019
Last update
Oct 25, 2021

Study contacts

Martin BENDSZUS, MD
principal investigator · University Hospital Heidelberg

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion